Register Login

Talaris Therapeutics Inc (TALS)

  • Event
  • Oct. 20, 2022, 11:12 UTC

(80% Positive) TALARIS THERAPEUTICS, INC. (TALS) Announces Enrollment Update for study Due to Patient Enrollment Issues, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 3, 2025, 9:34 a.m.

    📋 TALARIS THERAPEUTICS, INC. (TALS) - Clinical Trial Update

    Filing Date: 2022-10-20

    Accepted: 2022-10-20 07:12:03

    Event Type: Clinical Trial Update

    Event Details:

    Talaris Therapeutics Inc (TALS) Announces Clinical Trial Update Talaris Therapeutics Inc (TALS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: study
    • Diseases/Conditions: living donor kidney transplant (LDKT) recipients
    • Clinical Stage: Phase 3, Clinical Trial
    • Collaboration: Phase 3 Clinical Trial BOSTON

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: Talaris Therapeutics Inc
    • CIK: 0001827506
    • Ticker Symbol: TALS
    • Period End Date: 2022-10-20
    • Document Type: 8-K

Search

News categories